Joy Y. Mootien

Mulhouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Experts' recommendations for the management of adult patients with cardiogenic shock.

Experts' recommendations for the management of adult patients with cardiogenic shock.

Journal: Annals of intensive care

Published: February 12, 2026

Experts' recommendations for the management of adult patients with cardiogenic shock.

Experts' recommendations for the management of adult patients with cardiogenic shock.

Journal: Archives of cardiovascular diseases

Published: January 09, 2026

sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial.

sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial.

Journal: Scientific reports

Published: August 27, 2024

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.

Journal: EBioMedicine

Published: July 17, 2024

Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study.

Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study.

Journal: Open forum infectious diseases

Published: August 28, 2023

The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference.

The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference.

Journal: Annals of intensive care

Published: April 18, 2023

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.

Journal: Critical care (London, England)

Published: October 06, 2022

3D-printed simulator for nasopharyngeal swab collection for COVID-19.

3D-printed simulator for nasopharyngeal swab collection for COVID-19.

Journal: Infectious diseases now

Published: December 01, 2021

A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France.

A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France.

Journal: The Journal of international medical research

Published: June 24, 2021

NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?

NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?

Journal: Disease markers

Published: May 18, 2021

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: March 17, 2021

Real-world evaluation of ceftolozane/tazobactam therapy and clinical outcomes in France.

Real-world evaluation of ceftolozane/tazobactam therapy and clinical outcomes in France.

Journal: Infectious diseases now

Published: January 06, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026